RecruitingNCT06136195
Mavoglurant or placebo for alcohol cravings and drinking
About this title
Read the official source — NCT06136195Medication studyAges 21–50United StatesAddiction
Understand this study
Who could participate?
Listed age limits: 21 years to 50 years.
What will I do during this study?
Participants attend two laboratory sessions and take a single dose of mavoglurant or placebo (an inactive comparison treatment) before each session, in randomized order. The sessions are separated by a five-to-eight-day washout period.
- Listed locations
- New Haven and 1 more locationSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: July 1, 2024
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 63
- Sponsor
- Yale University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 21 Years to 50 Years
- Official registry ID
- NCT06136195
- Official title
Show the full official title
Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
New Haven
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Yale University, a university.
Does this study involve medication?
Yes. The study involves medication, including Mavoglurant.
Who can participate?
Listed age limits: 21 years to 50 years.
Is this study still recruiting?
The registry lists this study as recruiting.
